Go to The Journal of Clinical Investigation
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
  • Physician-Scientist Development
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Immunology
    • Metabolism
    • Nephrology
    • Oncology
    • Pulmonology
    • All ...
  • Videos
  • Collections
    • In-Press Preview
    • Resource and Technical Advances
    • Clinical Research and Public Health
    • Research Letters
    • Editorials
    • Perspectives
    • Physician-Scientist Development
    • Reviews
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • In-Press Preview
  • Resource and Technical Advances
  • Clinical Research and Public Health
  • Research Letters
  • Editorials
  • Perspectives
  • Physician-Scientist Development
  • Reviews
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
Whole-body deletion of Endospanin 1 protects from obesity-associated deleterious metabolic alterations
Arturo Roca-Rivada, … , Ralf Jockers, Julie Dam
Arturo Roca-Rivada, … , Ralf Jockers, Julie Dam
Published May 8, 2024
Citation Information: JCI Insight. 2024;9(9):e168418. https://doi.org/10.1172/jci.insight.168418.
View: Text | PDF
Research Article Cell biology Metabolism

Whole-body deletion of Endospanin 1 protects from obesity-associated deleterious metabolic alterations

  • Text
  • PDF
Abstract

The importance of the proper localization of most receptors at the cell surface is often underestimated, although this feature is essential for optimal receptor response. Endospanin 1 (Endo1) (also known as OBRGRP or LEPROT) is a protein generated from the same gene as the human leptin receptor and regulates the trafficking of proteins to the surface, including the leptin receptor. The systemic role of Endo1 on whole-body metabolism has not been studied so far. Here, we report that general Endo1-KO mice fed a high-fat diet develop metabolically healthy obesity with lipid repartitioning in organs and preferential accumulation of fat in adipose tissue, limited systematic inflammation, and better controlled glucose homeostasis. Mechanistically, Endo1 interacts with the lipid translocase CD36, thus regulating its surface abundance and lipid uptake in adipocytes. In humans, the level of Endo1 transcripts is increased in the adipose tissue of patients with obesity, but low levels rather correlate with a profile of metabolically healthy obesity. We suggest here that Endo1, most likely by controlling CD36 cell surface abundance and lipid uptake in adipocytes, dissociates obesity from diabetes and that its absence participates in metabolically healthy obesity.

Authors

Arturo Roca-Rivada, Marcio Do Cruzeiro, Raphaël G.P. Denis, Qiang Zhang, Christine Rouault, Yves Rouillé, Jean-Marie Launay, Céline Cruciani-Guglielmacci, Virginie Mattot, Karine Clément, Ralf Jockers, Julie Dam

×

Figure 5

Absence of Endo1 correlates with improved glucose homeostasis in obese mice.

Options: View larger image (or click on image) Download as PowerPoint
Absence of Endo1 correlates with improved glucose homeostasis in obese m...
(A) I.p. glucose tolerance test (IPGTT) after a 4-week HFD. Results are expressed as mean ± SEM (n ≥ 8). *P < 0.05; **P < 0.01; ****P < 0.001 versus WT. Two-way ANOVA with Bonferroni correction. AUC of the IPGTT (right panel). **P < 0.01 versus WT. ††P < 0.01; ††††P < 0.001 versus CD. One-way ANOVA with Bonferroni correction. (B) Plasma glucose and insulin levels after 16 hours of fasting. Results are expressed as mean ± SEM (n ≥ 7). **P < 0.01 versus WT; ††††P < 0.001 versus CD. One-way ANOVA with Bonferroni correction. (C) Assessment of the homeostatic model of insulin resistance (HOMA-IR). Results are expressed as mean ± SEM (n ≥ 7). **P < 0.01 versus WT; ††††P < 0.001 versus CD. One-way ANOVA with Bonferroni correction. (D) Insulin tolerance test (ITT) after 6-hour fasting on mice fed a 12-week HFD or CD. Results are expressed as mean ± SEM (n ≥ 8). *P < 0.05 versus WT. Two-way ANOVA with 2-stage linear step-up procedure of Benjamini, Krieger, and Yekutieli correction. (E) Blood glucose levels during ITT normalized with fasting glycemia. Results are expressed as mean ± SEM (n ≥ 8). Two-way ANOVA with 2-stage linear step-up procedure of Benjamini, Krieger, and Yekutieli correction.

Copyright © 2025 American Society for Clinical Investigation
ISSN 2379-3708

Sign up for email alerts